NEW YORK (TheStreet) -- RATINGS CHANGES
Edwards Lifesciences (EW) was upgraded at J.P. Morgan to overweight from neutral. Twelve-month price target is $155. The long-term story is more than intact, stronger today than it was two months ago, as analysts' confidence in the conversion of the SAVR market (surgical valve replacement) to TAVR (transcatheter replacement) increased significantly at this year's annual meeting of the American College of Cardiology, J.P. Morgan said.
Gap (GPS) was downgraded at FBR Capital Markets to market perform from outperform. Twelve-month price target is $40. Company will likely see lower margins, FBR Capital Markets said.
Infinera (INFN) was initiated with a buy rating at Deutsche Bank. Analysts have a differentiated long view, noting INFN as a pure play on the "Cloud Optical" opportunity -- i.e., 40/100G+ optical data-center interconnects for Web 2.0 and Cloud seeing mid double-digit capex spending CAGR, Deutsche Bank said.
Juniper (JNPR) was upgraded at Bank of America/Merrill to buy from neutral. Twelve-month price target is $34. New products should drive growth in the coming quarters, Bank of America/Merrill Lynch said.